MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $175.71M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.17M
Average 0.09M
MDWD Total Current Liabilities
All obligations due within one year.
MediWound Ltd.NASDAQ: MDWD
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities broadly unchanged from a year ago
Total current liabilities stood at $21.65M at the end of Q1 FY2026, down 0.9% from a year earlier and down 15.8% from the prior quarter. Over 3 fiscal years it compounded at +28.7% a year.
Context
- Total current liabilities amounted to 27.1% of total assets at the end of Q1 FY2026, down 4.6 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -0.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 25.71M USD
- Year-over-year change
- -3.1%
- 4-year CAGR
- +24.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.71M | -3.1% |
| FY2024 | 2024-12-31 | 26.54M | +145.1% |
| FY2023 | 2023-12-31 | 10.83M | -10.2% |
| FY2022 | 2022-12-31 | 12.06M | +12.5% |
| FY2021 | 2021-12-31 | 10.72M | — |
Total Current Liabilities vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -0.9% is the 6th highest of 10, against a peer median of +6.3%.
- Total current liabilities amounts to 27.1% of total assets for MDWD, versus a peer median of 11.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €77.35M EUR | -35.9% | +36.1% | 31.1% | |
| Mar 2026 | $31.66M USD | -36.2% | +10.9% | 13.1% | |
| Mar 2026 | $21.65M USD | -0.9% | +28.7% | 27.1% | |
| Mar 2026 | $16.29M USD | -9.8% | — | 489.1% | |
| Mar 2026 | $15.95M USD | +6.3% | -15.9% | 5.5% | |
| Mar 2026 | $13.69M USD | -11.6% | -3.4% | 13.6% | |
| Mar 2026 | $11.6M USD | +94.2% | +160.7% | 11.8% | |
| Sep 2026 | $9.29M USD | +56.7% | -23.2% | 6.6% | |
| Mar 2026 | $8.92M USD | +27.1% | +24.0% | 4.6% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $7.39M USD | +235.8% | +10.8% | 5.1% |
| Peer median (excluding MDWD) | — | +6.3% | +10.8% | 11.8% | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.05M | 33.9M | 11.87M | 9.16M | 4.8M |
| Short-term Investments | 0 | 0 | 29.68M | 34.01M | 48.34M |
| Net Receivables | 2.27M | 9.7M | 4.42M | 5.85M | 2.37M |
| Inventory | 1.2M | 1.96M | 2.85M | 2.69M | 4.09M |
| Other Current Assets | 0 | 363K | 167K | 0 | 0 |
| Total Current Assets | 14.95M | 45.84M | 49.7M | 52.16M | 59.96M |
| Property, Plant & Equipment (Net) | 4.03M | 3.58M | 15.93M | 20.8M | 25.79M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 297K | 231K | 165K | 99K | 33K |
| Long-term Investments | 469K | 364K | 490K | 439K | 467K |
| Tax Assets | (469K) | (364K) | 0 | 0 | 0 |
| Other Non-current Assets | (4.32M) | (3.81M) | 183K | 0 | 0 |
| Total Non-current Assets | 4.79M | 4.18M | 16.76M | 21.33M | 26.29M |
| Total Assets | 19.74M | 50.02M | 66.46M | 73.5M | 86.26M |
| Account Payables | 4.69M | 5.66M | 4.22M | 4.1M | 3.61M |
| Short-term Debt | 0 | 0 | 0 | 418K | 623K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 543K | 63K | 24K | 12K | 0 |
| Other Current Liabilities | 3.85M | 3.87M | 1.86M | 17.73M | 18.43M |
| Total Current Liabilities | 10.72M | 12.06M | 10.83M | 26.54M | 25.71M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 119K | 0 | 0 | 736K | 0 |
| Other Non-current Liabilities | 12.1M | 26.2M | 10.39M | 8.55M | 472K |
| Total Non-current Liabilities | 13.61M | 27.05M | 16.74M | 15.8M | 8.62M |
| Total Liabilities | 24.33M | 39.1M | 34.86M | 42.34M | 34.33M |
| Common Stock | 75K | 143K | 184K | 215K | 258K |
| Retained Earnings | (148.51M) | (168.11M) | (174.82M) | (205.05M) | (228.93M) |
| Accumulated OCI | (19K) | (5K) | (18K) | (11K) | (32K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (4.58M) | 10.91M | 31.6M | 31.15M | 43.63M |
| Total Debt | 1.39M | 846K | 6.35M | 6.93M | 8.77M |
| Net Debt | (9.66M) | (33.05M) | (5.52M) | (2.22M) | 3.98M |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.